Focused Report: Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy (CRT): Implications for Driving a Commercial Motor Vehicle (CMV)
MANILA Consulting Group, Inc. (2011). Focused Report: Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy (CRT): Implications for Driving a Commercial Motor Vehicle (CMV). United States. Department of Transportation. Federal Motor Carrier Safety Administration. https://doi.org/10.21949/1502951
MANILA Consulting Group, Inc.. Focused Report: Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy (CRT): Implications for Driving a Commercial Motor Vehicle (CMV). United States. Department of Transportation. Federal Motor Carrier Safety Administration, 2011. https://doi.org/10.21949/1502951.
MANILA Consulting Group, Inc. Focused Report: Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy (CRT): Implications for Driving a Commercial Motor Vehicle (CMV). United States. Department of Transportation. Federal Motor Carrier Safety Administration, 2011, ROSA P. https://doi.org/10.21949/1502951.
Details
Alternative Title:
Implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) : implications for driving a commercial motor vehicle (CMV)
NTL-FREIGHT-Trucking Industry
;
NTL-SAFETY AND SECURITY-Accidents
;
NTL-SAFETY AND SECURITY-Highway Safety
;
NTL-SAFETY AND SECURITY-Human Factors
Abstract:
This report was prepared by MANILA Consulting Group, Inc. under Contract No. GS-10F-0177N; Order No. DTMC75-10-F-00013, entitled ?Medical Programs Research and Analysis Panels Project, with the Department of Transportation’s Federal Motor Carrier Safety Administration. This document is intended to provide a focused assessment of current indications for and use of implantable cardioverter defibrillators (ICDs) combined with pacemakers in the general population, and implications for CMV drivers relative to FMCSA’s medical qualifications for driving.
MANILA Consulting Group, Inc. (2011). Focused Report: Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy (CRT): Implications for Driving a Commercial Motor Vehicle (CMV). United States. Department of Transportation. Federal Motor Carrier Safety Administration. https://doi.org/10.21949/1502951
MANILA Consulting Group, Inc.. Focused Report: Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy (CRT): Implications for Driving a Commercial Motor Vehicle (CMV). United States. Department of Transportation. Federal Motor Carrier Safety Administration, 2011. https://doi.org/10.21949/1502951.
MANILA Consulting Group, Inc. Focused Report: Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy (CRT): Implications for Driving a Commercial Motor Vehicle (CMV). United States. Department of Transportation. Federal Motor Carrier Safety Administration, 2011, ROSA P. https://doi.org/10.21949/1502951.
ROSA P serves as an archival repository of USDOT-published products including scientific
findings, journal articles, guidelines, recommendations, or other information authored or co-authored by
USDOT or funded partners. As a repository, ROSA P retains documents in their original published format to
ensure public access to scientific information.
Links with this icon indicate that you are leaving a Bureau of Transportation
Statistics (BTS)/National Transportation Library (NTL)
Web-based service.
Thank you for visiting.
You are about to access a non-government link outside of
the U.S. Department of Transportation's National
Transportation Library.
Please note: While links to Web sites outside of DOT are
offered for your convenience, when you exit DOT Web sites,
Federal privacy policy and Section 508 of the Rehabilitation
Act (accessibility requirements) no longer apply. In
addition, DOT does not attest to the accuracy, relevance,
timeliness or completeness of information provided by linked
sites. Linking to a Web site does not constitute an
endorsement by DOT of the sponsors of the site or the
products presented on the site. For more information, please
view DOT's Web site linking policy.
To get back to the page you were previously viewing, click
your Cancel button.